Anavex Life Sciences Reports Phase 2b/3 Trial Results of Once Daily Oral Alzheimer’s Treatment Blarcamesine
Anavex Life Sciences (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and neurodevelopmental disorders, announced significant…